Zai Lab outlines 2026 transition year with multiple late-stage catalysts and targets first global approval by 2028
Source: SeekingAlpha
2026-02-26 13:48:42 ET
More on Zai Lab
- Zai Lab Limited (ZLAB) Q4 2025 Earnings Call Transcript
- Zai Lab Limited (ZLAB) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
- Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Zai Lab Q4 2025 Earnings Preview
- ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025
Read the full article on Seeking Alpha
For further details see:
Zai Lab outlines 2026 transition year with multiple late-stage catalysts and targets first global approval by 2028
Zai Lab Limited
NASDAQ: ZLAB
ZLAB Trading
-0.16% G/L:
$19.27 Last:
324,394 Volume:
$19.06 Open:
ZLAB Latest News
February 26, 2026 07:00:00 am
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
ZLAB Stock Data
$2,174,273,322
105,108,310
0.9%
39
N/A
Biotechnology & Life Sciences
Healthcare
CN
Shanghai
